Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro

International Journal of Antimicrobial Agents

Volumn 18, Issue 2, 2001, Pages 107-112

  Ruiz, Joaquim ^a   Sierra, Josep M ^a   De Anta, M Teresa Jiménez ^a   Vila, Jordi ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Efflux pumps; GyrA; Quinolones; Resistance; S. aureus; Sparfloxacin

Indexed keywords

CIPROFLOXACIN; NORFLOXACIN; SPARFLOXACIN;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POINT MUTATION; SEQUENCE ANALYSIS, DNA; STAPHYLOCOCCUS AUREUS;

EID: 0034889825     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(01)00366-1     Document Type: Article

References (36)

1. Antibacterial activity of trovafloxacin against nosocomial gram-positive and gram-negative isolates
2. Ciprofloxacin an updated review of its pharmacology, therapeutic efficacy and tolerability
3. Comparative activities of clinafloxacin against gram-positive and -negative bacteria
4. The comparative in-vitro activity of eight newer quinolones and nalidixic acid
5. In vitro activity of ciprofloxacin against methicillin-sensitive and methicillin-resistant Staphylococci
6. The epidemiology of bacterial resistance to quinolones
7. Analysis of the mechanism of quinolone-resistance in nalidixic acid-resistant clinical isolates of Salmonella serotype Typhimurium
8. Increased resistance in Campylobacter jejuni. A genetic analysis of gyrA gene mutation in ciprofloxacin resistant clinical isolates
9. In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens
10. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against gram-positive bacteria
11. Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity
12. Escherichia coli topoisomerase IV. Purification, characterization, subunit structure and subunit interactions
13. Mechanism of action of nalidixic acid: Purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme
14. Topoisomerase IV is a target of quinolones in Escherichia coli
15. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones
16. parC subunit of DNA Topoisomerase IV is a primary target of fluoroquinolones and co-operates with DNA Gyrase A subunit in forming resistance phenotype
17. Quinolone resistance mutations in topoisomerase IV: Relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA Gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus
18. Comparison of ciprofloxacin, trovafloxacin, and sparfloxacin for selecting topoisomerase II mutations in Streptococcus pneumoniae
19. Targeting of DNA Gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones
20. Streptococcus pneumoniae DNA Gyrase and Topoisomerase IV overexpression, purification, and differential inhibition by fluoroquinolones
21. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli
22. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus
23. Characterization of grlA, grlB, gyrA and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC
24. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs
25. Proton-dependent multidrug efflux systems
26. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus
27. Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus
28. Quinolone-resistance mediated by NorA: Physiologic characterization and relationship to flqB, a quinolone resistance locus on Staphylococcus aureus chromosome
29. A point mutation in norA gene is responsible for quinolone resistance in Staphylococcus aureus
30. Laboratory diagnosis of oxacillin resistance in Staphylococcus aureus by a multiplex-polymerase chain reaction assay
31. Prevalence of two different genes, encoding NorA, in 23 clinical strains of Staphylococcus aureus
32. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones
33. Efflux-mediated fluoroquinolone resistance in genetically related strains of Staphylococcus aureus
34. Relationship between mutations in the coding and promoter regions of the NorA genes in 42 unrelated clinical isolates of Staphylococcus aureus and MICs of norfloxacin for these strains
35. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter
36. Evidence for the existence of a multidrug efflux transporter distinct from NorA in Staphylococcus aureus